Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Int J Oncol. 2013 Sep;43(3):911-8. doi: 10.3892/ijo.2013.2005. Epub 2013 Jul 5.
The purpose of our study was to determine the effect of the combined action of phytochemicals on the early stages of skin tumorigenesis, i.e. initiation and promotion. We tested calcium D-glucarate (CG) given in the diet, while resveratrol (RES) and ursolic acid (UA) were applied topically. The 7,12-dimethylbenz[a]anthracene (DMBA)-initiated, 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted multistage skin carcinogenesis model in SENCAR mice was used. Mice received one topical dose of DMBA, then after one month, two weekly doses of TPA for 14 weeks until sacrifice. RES or UA were applied 20 min prior to DMBA or TPA treatment and 2% dietary CG was given from 2 weeks prior to 2 weeks after the DMBA dose or continually beginning 2 weeks prior to the first dose of TPA. UA applied alone and in combination with CG during the promotion stage was the only inhibitor of tumor multiplicity and tumor incidence. A number of combinations reduced epidermal proliferation, but only UA and the combination UA+CG applied during promotion significantly reduced epidermal hyperplasia. DMBA/TPA application resulted in significant increases in c-jun and p50, which were reversed by a number of different treatments. DMBA/TPA treatment also strongly increased mRNA levels of inflammation markers COX-2 and IL-6. All anti-promotion treatments caused a marked decrease in COX-2 and IL-6 expression compared to the DMBA/TPA control. These results show that UA is a potent inhibitor of skin tumor promotion and inflammatory signaling and it may be useful in the prevention of skin cancer and other epithelial cancers in humans.
我们的研究目的是确定植物化学物质的联合作用对皮肤肿瘤发生的早期阶段(即引发和促进)的影响。我们在饮食中测试了葡萄糖酸钙(CG),同时局部应用白藜芦醇(RES)和熊果酸(UA)。我们使用了 7,12-二甲基苯并[a]蒽(DMBA)引发,12-O-十四烷酰佛波醇-13-乙酸酯(TPA)促进的 SENCAR 小鼠多阶段皮肤致癌模型。小鼠接受了一次 DMBA 局部剂量,然后一个月后,接受了两周一次的 TPA 治疗,共 14 周,直到处死。RES 或 UA 在 DMBA 或 TPA 处理前 20 分钟应用,2%饮食 CG 从 DMBA 剂量前 2 周给予至剂量后 2 周或从第一剂 TPA 前 2 周开始持续给予。在促进阶段单独和与 CG 联合应用的 UA 是肿瘤多发性和肿瘤发生率的唯一抑制剂。一些组合减少了表皮增殖,但只有 UA 和在促进阶段应用的 UA+CG 组合显著减少了表皮增生。DMBA/TPA 应用导致 c-jun 和 p50 的显著增加,这些增加被许多不同的治疗方法逆转。DMBA/TPA 处理还强烈增加了炎症标志物 COX-2 和 IL-6 的 mRNA 水平。与 DMBA/TPA 对照相比,所有抗促进处理都导致 COX-2 和 IL-6 表达明显下降。这些结果表明 UA 是皮肤肿瘤促进和炎症信号的有效抑制剂,它可能对预防人类皮肤癌和其他上皮癌有用。